Touting a $4 Stock with $28M in sales that has a new drug in Phase trials for Uveitis – eye disease. It has been granted ”Orphan Status” by FDA and Phase trial data is due out very soon. ?What is the stock and is this real? He wants $1950 for one year subscription to the newsletter.
This is a discussion topic or guest posting submitted by a Stock Gumshoe reader. The content has not been edited or reviewed by Stock Gumshoe, and any opinions expressed are those of the author alone.